BOYD B ET AL: "Lapatanib: Oncolytic dual EGFR and erbB-2 inhibitor" DRUGS OF THE FUTURE 200512 ES, vol. 30, no. 12, December 2005 (2005-12), pages 1225-1239, XP002553861 ISSN: 0377-8282 (B1)

HEYMACH J V ET AL: "Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer" CLINICAL CANCER RESEARCH 20060715 US, vol. 12, no. 14, 15 July 2006 (2006-07-15), pages 4441s-4445s, XP002553862 ISSN: 1078-0432 (B1)

JACKISCH ET AL: "Challenges in the treatment of ErbB2 (HER2)-positive breast cancer" EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 6, no. 5, 1 March 2008 (2008-03-01), pages 7-14, XP022559516 ISSN: 1359-6349 (B1)

LORUSSO P M ET AL: "Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology" EXPERT OPINION ON INVESTIGATIONAL DRUGS 200807 GB, vol. 17, no. 7, July 2008 (2008-07), pages 1013-1028, XP002553860 ISSN: 1354-3784 (B1)

OCANA A ET AL: "Identifying breast cancer druggable oncogenic alterations: Lessons learned and future targeted options" CLINICAL CANCER RESEARCH 20080215 US, vol. 14, no. 4, 15 February 2008 (2008-02-15), pages 961-970, XP002553863 ISSN: 1078-0432 (B1)

RABINDRAN S K ET AL: "Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 64, no. 11, 1 January 2004 (2004-01-01), pages 3958-3965, XP002318446 ISSN: 0008-5472 (B1)

WO-A-2009/042613 (B1)

WO-A-2006/081985 (B1)

WO-A-2006/113151 (B1)

WO-A-2006/120557 (B1)

WO-A-2007/056118 (B1)

WO-A-2008/076143 (B1)

WO-A-2005/018677 (B1)